Acura Pharmaceuticals borrows $141,607 from AD Pharma; note balance hits $11.44M with going-concern warning

ACURA PHARMACEUTICALS, INC

• Two new loans of $41,607 (Oct 19, 2026) and $100,000 (Oct 30, 2026) from Abuse Deterrent Pharma bring the secured note principal to $11,435,886.
• Accrued interest is approximately $1,416,000 as of October 31, 2026; the note bears 5.25% interest, rising to 7.5% on overdue amounts.
• Acura says without additional financing by late-November 2026 it must furlough or lay off employees, terminate operations, or seek bankruptcy protection.
• AD Pharma agreement requires FDA acceptance of an NDA for LTX-03 by December 31, 2026, and payoff of the secured note by the same date.
• Loan #66 of $100,000 on October 2, 2026 preceded the two disclosed loans; total aggregated principal rose from $2,319,279 in November 2022.